[1]邓克红,王晨阳,王武亮#.西妥昔单抗联合奈达铂对宫颈癌Hela细胞增殖的影响*[J].郑州大学学报(医学版),2014,(01):99.
 DENG Kehong,WANG Chenyang,WANG Wuliang.Effects of nedaplatin combined with cetuximab on proliferation of cervical carcinoma Hela cell line[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2014,(01):99.
点击复制

西妥昔单抗联合奈达铂对宫颈癌Hela细胞增殖的影响*
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2014年01期
页码:
99
栏目:
应用研究
出版日期:
2014-01-20

文章信息/Info

Title:
Effects of nedaplatin combined with cetuximab on proliferation of cervical carcinoma Hela cell line
作者:
邓克红王晨阳王武亮#
郑州大学第二附属医院妇产科 郑州 450014
Author(s):
DENG KehongWANG ChenyangWANG Wuliang
Department of Gynaecology and Obstetrics,the Second Affiliated Hospital,Zhengzhou University, Zhengzhou 450014
关键词:
西妥昔单抗奈达铂Hela细胞表皮生长因子受体
Keywords:
cetuximabnedaplatinHela cell lineEGFR
分类号:
R711.7
摘要:
目的:探讨西妥昔单抗(C225)与奈达铂(NDP)联合应用对Hela细胞增殖的影响。方法:培养宫颈癌Hela细胞,分为C225单药组(C225的质量浓度依次是10、20、40、60、80和160 mg/L)、NDP单药组(NDP的质量浓度依次是1、5、10、20、40和60 mg/L)、C225+NDP联合用药组(40 mg/L C225 分别联合不同质量浓度的NDP)。每个质量浓度分别作用Hela细胞24、48和72 h后用MTT法检测细胞增殖抑制率。结果:C225单药不能抑制Hela细胞增殖,随着药物质量浓度的增加和作用时间的延长,细胞增殖抑制率的变化差异无统计学意义(P>0.05)。NDP单药对Hela细胞有明显抑制作用,随着药物质量浓度的增加(F=3 200.480,P<0.001)和作用时间的延长(F=3 057.250, P<0.001),细胞的增殖抑制率逐渐增加,浓度和时间存在交互作用(F=99.701,P<0.001)。C225联合NDP用药的细胞增殖抑制率明显高于对应的C225或NDP单药,差异有统计学意义(F=39.507,P<0.001)。结论:C225可增强Hela细胞对NDP化疗的敏感性。
Abstract:
Aim: To study the effects of nedaplatin(NDP) combined with cetuximab(C225) on the proliferation of cervical carcinoma Hela cell line. Methods: The Hela cells were allocated into C225 groups, NDP groups and combination groups of C225 and NDP(C225+NDP groups). The concentration of C225 groups was 10,20,40,60,80 and 160 mg/L,the concentration of NDP groups was 1,5,10,20,40 and 60 mg/L;and that of C225+NDP groups was 40 mg/L C225 plus NDP at different concentrations. Hela cells were treated for 24 h, 48 h, 72 h. The inhibitory effects of C225 and NDP on the Hela cells were evaluated by MTT. Results: C225 had no inhibitive effects on Hela cells with the increased concentrations and time(P>0.05). NDP could significantly inhibited the growth of Hela cells, and the inhibition showed concentration and time dependence and interaction(F=3 200.480,3 057.250, and 99.201,P<0.001). The combination of C225 and DNP had better inhibitive effects on Hela cells than single use of C225 or NDP(F=39.507,P<0.001).Conclusion: C225 could enhance the inhibition effects of NDP on Hela cell line.

参考文献/References:

[1]姚安梅,李春燕,高尚风,等.局部晚期宫颈癌患者综合治疗的可行性分析[J].西安交通大学学报:医学版,2013,34(3):375 [2]Kim SJ,Rabbani ZN,Dong F,et al.Phosphorylated epidermal growth factor receptor and cyclooxygenase2 expression in localized nonsmall cell lung cancer[J].Med Oncol,2010,27(1):91 [3]薛琴琴,张菊,俞青苗,等.宫颈癌组织表皮生长因子受体对TKI敏感性相关的基因突变研究[J].西安交通大学学报:医学版,2012,33(5):583 [4]王海荣,于长华,朱卫国,等.奈达铂与顺铂在宫颈癌同步放化疗中的应用[J].实用妇产科杂志,2011,27(10):771 [5]Ettinger DS.Clinical implications of EGFR expression in the development and progression of solid tumors: focus on nonsmall cell lung cancer[J].Oncologist,2006,11(4):358 [6]王利娟,田园,高积勇.宫颈癌预后与表皮生长因子受体蛋白表达的关系[J].中国妇幼健康研究,2006,17(4):280 [7]吴仁瑞,吴少雄,赵充,等.hR3联合放疗治疗局部晚期鼻咽癌的Ⅱ期临床研究[J].癌症,2007,26(8):874 [8]Harari PM.Epidermal growth factor receptor inhibition strategies in oncology[J].Endocr Relat Cancer,2004,11(4):689 [9]Koshiyama M,Kinezaki M,Uchida T,et al.Chemosensitivity testing of a novel platinum analog, nedaplatin (254S), in human gynecological carcinomas: a comparison with cisplatin[J].Anticancer Res,2005,25(6C):4499 [10]Desoize B,Madoulet C.Particular aspects of platinum compounds used at present in cancer treatment[J].Crit Rev Oncol Hematol,2002,42(3):317 [11]Bowers G,Reardon D,Hewitt T,et al.The relative role of ErbB14 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells[J].Oncogene,2001,20(11):1388

相似文献/References:

[1]彭方慧,王峰,何炜,等.替吉奥与5氟尿嘧啶联合奈达铂治疗晚期食管癌的疗效比较*[J].郑州大学学报(医学版),2013,(02):160.
 PENG Fanghui,WANG Feng,HE Wei,et al.Comparison of clinical efficacy of advanced esophageal cancer treated with S1 and 5fluorouracil combined with nedaplatin[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2013,(01):160.

备注/Memo

备注/Memo:
*河南省卫生厅科技攻关项目201203043;#通讯作者,男,1963年11月生,本科,主任医师,研究方向:妇科肿瘤,Email: wangwuliang888@sina.com
更新日期/Last Update: 2014-02-20